SG11201804123VA - Modulators of kv3 channels to treat pain - Google Patents
Modulators of kv3 channels to treat painInfo
- Publication number
- SG11201804123VA SG11201804123VA SG11201804123VA SG11201804123VA SG11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- stevenage
- autifony
- bioscience
- pct
- Prior art date
Links
- 241000581479 Apodichthys Species 0.000 abstract 3
- 239000003054 catalyst Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000002023 wood Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 241000566137 Sagittarius Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521751.6A GB201521751D0 (en) | 2015-12-10 | 2015-12-10 | Novel uses |
| PCT/GB2016/053879 WO2017098254A1 (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804123VA true SG11201804123VA (en) | 2018-06-28 |
Family
ID=55274489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804123VA SG11201804123VA (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11147813B2 (pt) |
| EP (1) | EP3386506B1 (pt) |
| JP (2) | JP7149847B2 (pt) |
| KR (1) | KR20180097549A (pt) |
| CN (2) | CN108472288B (pt) |
| AU (1) | AU2016367239B2 (pt) |
| BR (1) | BR112018011700B1 (pt) |
| CA (1) | CA3005302A1 (pt) |
| DK (1) | DK3386506T3 (pt) |
| EA (1) | EA038059B1 (pt) |
| ES (1) | ES2974902T3 (pt) |
| FI (1) | FI3386506T3 (pt) |
| GB (1) | GB201521751D0 (pt) |
| HR (1) | HRP20240497T1 (pt) |
| HU (1) | HUE066879T2 (pt) |
| IL (1) | IL259717B (pt) |
| MX (1) | MX2018007074A (pt) |
| PL (1) | PL3386506T3 (pt) |
| PT (1) | PT3386506T (pt) |
| SG (1) | SG11201804123VA (pt) |
| WO (1) | WO2017098254A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| WO2018109484A1 (en) | 2016-12-16 | 2018-06-21 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018220762A1 (ja) | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| WO2020079422A1 (en) | 2018-10-16 | 2020-04-23 | Autifony Therapeutics Limited | Novel compounds |
| US20210276985A1 (en) * | 2018-10-16 | 2021-09-09 | Autifony Therapeutics Limited | Novel compounds |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| CN115066424A (zh) | 2020-02-06 | 2022-09-16 | 奥蒂福尼疗法有限公司 | Kv3调节剂 |
| JP2024530208A (ja) | 2021-08-10 | 2024-08-16 | アウトイフオンイ トヘラペウトイクス リミテッド | カリウムチャネルモジュレーター |
| CN113788741B (zh) * | 2021-09-28 | 2023-12-29 | 大连九信精细化工有限公司 | 一种制备2-环丙基苯酚衍生物的方法 |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110033149A (ko) | 2008-06-06 | 2011-03-30 | 유씨비 파마, 에스.에이. | 시클로부톡시기를 포함하는 화합물 |
| ES2575215T3 (es) * | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
| JP5913357B2 (ja) * | 2010-12-06 | 2016-04-27 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤として有用なヒダントイン誘導体 |
| EP2718285B1 (en) | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| EP2788339B1 (en) * | 2011-12-06 | 2016-03-09 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| JP2015517563A (ja) | 2012-05-22 | 2015-06-22 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
| JP6240667B2 (ja) * | 2012-05-22 | 2017-11-29 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのトリアゾール |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
-
2015
- 2015-12-10 GB GBGB1521751.6A patent/GB201521751D0/en not_active Ceased
-
2016
- 2016-12-09 EP EP16813020.1A patent/EP3386506B1/en active Active
- 2016-12-09 JP JP2018529633A patent/JP7149847B2/ja active Active
- 2016-12-09 EA EA201891377A patent/EA038059B1/ru unknown
- 2016-12-09 WO PCT/GB2016/053879 patent/WO2017098254A1/en active Application Filing
- 2016-12-09 FI FIEP16813020.1T patent/FI3386506T3/fi active
- 2016-12-09 CA CA3005302A patent/CA3005302A1/en active Pending
- 2016-12-09 AU AU2016367239A patent/AU2016367239B2/en active Active
- 2016-12-09 CN CN201680072639.8A patent/CN108472288B/zh active Active
- 2016-12-09 HR HRP20240497TT patent/HRP20240497T1/hr unknown
- 2016-12-09 PL PL16813020.1T patent/PL3386506T3/pl unknown
- 2016-12-09 BR BR112018011700-5A patent/BR112018011700B1/pt active IP Right Grant
- 2016-12-09 MX MX2018007074A patent/MX2018007074A/es unknown
- 2016-12-09 CN CN202410102663.8A patent/CN118267386A/zh active Pending
- 2016-12-09 DK DK16813020.1T patent/DK3386506T3/da active
- 2016-12-09 HU HUE16813020A patent/HUE066879T2/hu unknown
- 2016-12-09 SG SG11201804123VA patent/SG11201804123VA/en unknown
- 2016-12-09 ES ES16813020T patent/ES2974902T3/es active Active
- 2016-12-09 PT PT168130201T patent/PT3386506T/pt unknown
- 2016-12-09 US US16/060,714 patent/US11147813B2/en active Active
- 2016-12-09 KR KR1020187017088A patent/KR20180097549A/ko not_active Application Discontinuation
-
2018
- 2018-05-30 IL IL259717A patent/IL259717B/en active IP Right Grant
-
2021
- 2021-09-10 US US17/472,493 patent/US11944623B2/en active Active
-
2022
- 2022-06-30 JP JP2022106247A patent/JP2022141699A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891377A1 (ru) | 2019-01-31 |
| GB201521751D0 (en) | 2016-01-27 |
| US20190000848A1 (en) | 2019-01-03 |
| DK3386506T3 (da) | 2024-05-06 |
| CN118267386A (zh) | 2024-07-02 |
| IL259717B (en) | 2021-05-31 |
| US11944623B2 (en) | 2024-04-02 |
| EA038059B1 (ru) | 2021-06-30 |
| HUE066879T2 (hu) | 2024-09-28 |
| US11147813B2 (en) | 2021-10-19 |
| JP2022141699A (ja) | 2022-09-29 |
| MX2018007074A (es) | 2018-12-12 |
| HRP20240497T1 (hr) | 2024-08-16 |
| PL3386506T3 (pl) | 2024-06-03 |
| JP2019506367A (ja) | 2019-03-07 |
| ES2974902T3 (es) | 2024-07-02 |
| IL259717A (en) | 2018-07-31 |
| JP7149847B2 (ja) | 2022-10-07 |
| AU2016367239B2 (en) | 2020-07-09 |
| EP3386506A1 (en) | 2018-10-17 |
| AU2016367239A1 (en) | 2018-06-07 |
| FI3386506T3 (fi) | 2024-04-23 |
| BR112018011700B1 (pt) | 2023-12-26 |
| CA3005302A1 (en) | 2017-06-15 |
| EP3386506B1 (en) | 2024-01-24 |
| WO2017098254A1 (en) | 2017-06-15 |
| CN108472288B (zh) | 2024-05-28 |
| BR112018011700A2 (pt) | 2018-11-27 |
| CN108472288A (zh) | 2018-08-31 |
| KR20180097549A (ko) | 2018-08-31 |
| US20220071998A1 (en) | 2022-03-10 |
| PT3386506T (pt) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900471VA (en) | Combination therapy for copd | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |